Published TCIMAIL newest issue No.197 | New tool "TCI SpectraViewer" | [Product Highlights] o-Nitrobenzyl Photolabile... | Product Document Searching Made Easy by 2D Code!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 202409-33-4 | Product Number: E1492
Etoricoxib
×
![]()
×
Purity: >95.0%(T)(HPLC)
Synonyms:
- 5-Chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine
- 5-Chloro-3-[4-(methylsulfonyl)phenyl]-2-(2-methyl-5-pyridinyl)pyridine
Product Documents:
| Size | Unit Price | Hyderabad | Japan* | Quantity |
|---|---|---|---|---|
| 200MG |
₹2,700.00
|
Contact Us | 4 |
|
| 1G |
₹8,900.00
|
1 | 13 |
|
*Upon orders receipt, Hyderabad stocks will be dispatched on the same day.
*Items available in Japan warehouse will be dispatched in 10-12 working days.
*INR price is exclusive of domestic taxes applicable.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | E1492 |
| Purity / Analysis Method | >95.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__8H__1__5ClN__2O__2S = 358.84 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Heat Sensitive |
| Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 202409-33-4 |
| Reaxys Registry Number | 8073797 |
| MDL Number | MFCD06797512 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 95.0 area% |
| Purity(Volumetric Analysis) | min. 95.0 % |
| Melting point | 133.0 to 137.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 135 °C |
GHS
Related Laws:
| RTECS# | DW1762210 |
Transport Information:
Application
Etoricoxib: A Selective Cyclooxygenase-2 (COX-2) Inhibitor
Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID), and a selective inhibitor of COX-2 (cyclooxygenase 2) with a higher COX-1 to COX-2 selectivity ratio than the other COX-2-selective inhibitors, such as rofecoxib [R0206], valdecoxib [V0133] or celecoxib [C2816]. The mechanism of action is mainly by inhibition of the enzyme COX in the arachidonic acid metabolism pathway, resulting in reduced prostaglandin synthesis. In theory, a drug that selectively inhibited COX-2 might block inflammation, pain, and fever produced by prostaglandins while reducing the side effects (gastric erosions and ulcers) associated with inhibition of COX-1. (The product is for research purpose only.)
References
- Etoricoxib (a review)
- Selective COX-2 inhibitors: a review of their structure-activity relationships (a review)
- RP-HPLC method for simultaneous estimation of Paracetamol and Etoricoxib from bulk and tablets
- Determination of etoricoxib in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionisation
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.